RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
Considering the high-growth stage of the COVID-19 breakout, here is the latest tally of cases from yesterday:
U.S.: 15,219 (10,442 prior) with 201 deaths (150 prior).
China: 81,250 (+95) with 3,253 deaths (+4).
Italy: 41,035 (+5,322) with 3,405 deaths (+427).
Spain: 19,980 (+6,070) with 1,002 deaths (+199).
3M Company (MMM -4.2%) announces that it has doubled its global output of N95 (masks that filter out 95% of micron-sized particles in testing) respirators to an annualized rate of more than 1.1B, adding that it has not increased prices due to the extraordinary demand (admits that it does not control the actions of dealers and retailers).
It plans to increase its investments in order expand global capacity by an additional 30% in the next 12 months.
It is also maximizing production of other COVID-19-related products such as hand sanitizers, disinfectants and filtration solutions.
Health Canada has approved ViiV Healthcare’s Cabenuva (cabotegravir and rilpivirine extended-release injectable suspensions), a once-monthly regimen for HIV-1-infected adults who are virologically stable and suppressed (HIV-1 RNA less than 50 copies/mL).
The company says Vocabria oral tablets can be used in conjunction with Cabenuva for short periods of time (Health Canada approved this as well).
The approvals are the first anywhere in the world.
ViiV Healthcare is the HIV-focused joint venture between GlaxoSmithKline (NYSE:GSK), Pfizer (NYSE:PFE) and Shionogi (OTCPK:SGIOY).
Nano cap Bellerophon Therapeutics (NASDAQ:BLPH) rockets 316% premarket on robust volume in reaction to the FDA’s granting of emergency use of INOpulse to treat COVID-19 patients.
CEO Fabian Tenenbaum says, “Based on currently available data and its significant role in the immune response, we believe INOpulse has the potential to be a safe and effective treatment for COVID-19. INOpulse technology utilizes targeted pulsatile delivery of inhaled nitric oxide, providing important antiviral potential, as well as improved arterial oxygenation. Importantly, INOpulse is designed to treat patients in the outpatient setting, which may be critical in helping combat the further spread of the virus and significantly alleviate the mounting impact on hospitals and intensive care units. We look forward to supporting patients and physicians in order to help address the current COVID-19 global health pandemic.”
Ascendis Pharma (NASDAQ:ASND) initiated with Outperform rating with a $199 (97% upside) price target at Oppenheimer.
Livongo Health (NASDAQ:LVGO) initiated with Buy rating and $30 (39% upside) price target at Stifel.
New Frontier Health (NFH) initiated with Outperform rating at Credit Suisse.
Cardinal Health (NYSE:CAH) upgraded to Buy with a $58 (32% upside) price target at Bank of America. Shares up 3% premarket.
Community Healthcare Trust (NYSE:CHCT) upgraded to Buy with a $40 (43% upside) price target at B. Riley FBR.
Gilead Sciences (NASDAQ:GILD) upgraded to Overweight with a $90 (15% upside) at Piper Sandler in anticipation of the FDA nod for remdesivir for COVID-19. Shares up 4% premarket.
Pacira BioSciences (NASDAQ:PCRX) upgraded to Outperform with a $44 (35% upside) price target at SVB Leerink.
Perrigo (NYSE:PRGO) upgraded to Outperform with a $52 (19% upside) price target at SVB Leerink.
UnitedHealth Group (NYSE:UNH) upgraded to Buy with a $308 (40% upside) price target at Deutsche Bank. Shares up 6% premarket.
